OI-3
OI-3 is a monoclonal antibody targeting CD146 (MCAM). OI-3 specifically binds to CD146 on the surface of human mesothelioma cells and undergoes endocytosis; both chimeric (chOI-3) and murine (mOI-3) variants possess this activity. When conjugated with 212Pb to form 212Pb-TCMC-OI-3, OI-3 acts as a cytotoxic agent that delivers α-emitting radionuclides to induce targeted cytotoxicity. OI-3 can be used in research related to malignant peritoneal mesothelioma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
Radionuclide-Drug Conjugates (RDCs) アイソフォーム固有の製品をすべて表示
More
生物活性
Human
Compared with mouse-derived OI-3 (mOI-3), chimeric OI-3 (chOI-3) exhibits higher apparent affinity for CD146 on the surface of human pleural mesothelioma cells MSTO-211H and NCI-H226; the KDAPP values of chOI-3 are 3.3 nM and 5.9 nM, respectively, while those of mOI-3 are 9.2 nM and 11.4 nM[1].
mOI-3 and chOI-3 (0.25 μg; 1-24 h) are efficiently internalized into MSTO-211H human mesothelioma cells, reaching the internalization peak at 6-24 h; in contrast, chOI-3 shows extremely weak internalization into NCI-H226 human mesothelioma cells within 24 h[1].
chOI-3 (0.25 μg/mL; 16 h) internalizes into the human pleural mesothelioma cell line MSTO-211H within 16 h, and its internalization rate in real-time live-cell imaging assays is significantly higher than that of the human IgG1 isotype control[1].
212Pb-TCMC-chOI-3 (5-10 kBq/mL; 2-24 h) is internalized into MSTO-211H human pleural mesothelioma cells. At 24 h, the number of internalized 212Pb and 212Bi atoms per cell is significantly higher than that at 2 h, reaching 13.7-fold and 8.5-fold of that of the isotype control, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hsd: Athymic Nude-Foxn1nu (female, 4-5 weeks old)[1]
-
Dosage:348 kBq (with 10 µg mOI-3 antibody, 5:1 TCMC-to-antibody ratio)
-
Administration:i.p.; single bolus
-
Result:Prolonged median survival time to 55 days, which was 23-29% longer than control groups (saline: 40 days, unlabeled mOI-3: 41 days, mIgG: 39 days, 212Pb-TCMC-mIgG: 42 days).
Showed significantly prolonged survival compared to saline-treated mice and unlabeled mOI-3 controls.
Exhibited no significant differences in body weight between treatment groups.
MUC18/MCAM/CD146
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
化学情報
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)